The CRL is a significant negative catalyst for a pre-revenue biotech with a single lead asset — expect substantial downside pressure on CING and CINGW. Monitor for the resubmission timeline and any additional financing needs; the $30M cash position provides a cushion but does not eliminate dilution risk if resubmission is protracted.
Price Chart
Executive Summary
Cingulate received a Complete Response Letter (CRL) from the FDA for its lead NDA, CTx-1301 (ADHD), citing only Chemistry, Manufacturing and Controls (CMC) information requests with no clinical safety or efficacy concerns. The company has nearly $30M cash on hand and expects a prompt resubmission. This is a material delay but not a clinical failure, and the company appears capitalized to address the issues.
Key Facts
- FDA issued a Complete Response Letter for CTx-1301 NDA on June 2, 2026
- CRL identified specific CMC information requests; no clinical safety or efficacy concerns raised
- Company expects prompt resubmission of requested information
- Company reports nearly $30 million cash on hand
- PDUFA target action date was May 31, 2026 — the CRL was issued the following business day
Financial Impact
CRL delays potential approval of lead asset CTx-1301 indefinitely; company has ~$30M cash to fund resubmission and operations into 2027
Risk Factors
- Resubmission may take longer than expected or require additional clinical/CMC data
- Potential need for additional capital if resubmission process extends beyond current cash runway
- CRL could signal broader manufacturing or regulatory challenges for the PTR platform
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026760 |
| Exhibit: ex99-1.htm | 0001493152-26-026760 |
| Document: 0001493152-26-026760-index-headers.html | 0001493152-26-026760 |
| Document: 0001493152-26-026760-index.html | 0001493152-26-026760 |
| Document: 0001493152-26-026760.txt | 0001493152-26-026760 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 2, 2026 20w ago | 8-K | $0.0601 $0.0114 | ▲ +81.03% | ▲ +82.15% | — |
May 19, 2026 22w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −93.02% | — |
May 14, 2026 23w ago | 8-K | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
May 14, 2026 23w ago | Press Release | $0.0601 $0.007200 | ▼ −88.02% | ▼ −91.61% | — |
Apr 27, 2026 26w ago | EFFECT | $0.0601 $0.0189 | ▲ +68.55% | ▲ +73.33% | — |
Mar 18, 2026 31w ago | Press Release | $0.0601 $0.0601 | · 0.00% | ▼ −11.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers